Drug therapy of Helicobacter pylori infection

Comparative evaluation of sequential therapy versus triple therapy and concomitant four-drug therapy for eradication of helicobacter pylori infection in children from 5 to 15 years old

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017062234698N1

Enrollment

120

Registered

2017-09-06

Start date

2017-09-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori infection. Helicobacter pylori [H.pylori] as the cause of diseases classified to other chapters

Interventions

Intervention 1: Group A: Omeprazole plus Amoxicillin plus Clarithromycin over ten days. Intervention 2: Group B: Omeprazole plus Amoxicillin in the first five days and then Omeprazole plus Metronid

Treatment - Drugs

Group A: Omeprazole plus Amoxicillin plus Clarithromycin over ten days

Group B: Omeprazole plus Amoxicillin in the first five days and then Omeprazole plus Metronidazole plus Clarithromycin over the next five days

Group C: Omeprazole plus Amoxicillin plus Clarithromycin plus Metronidazole over ten days

Eligibility

Sex/Gender

All

Age

5 Years to 15 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients with digestive disorders such as recurrent abdominal pain; gastrointestinal bleeding and dyspepsia. Exclusion criteria: having a history of taking medications such as antibiotics; bismuth; proton pump inhibitors; Histamine receptor antagonists and non steroid anti inflammatory drugs in the last 4 weeks.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Helicobacter pylori in the corpus specimen. Timepoint: Four weeks after the last day of treatment. Method of measurement: Standard protocol.;Histopathology of stomach biopsy. Timepoint: Four weeks after the last day of treatment. Method of measurement: Standard protocol.;Helicobacter pylori in anther sample. Timepoint: Four weeks after the last day of treatment. Method of measurement: Standard protocol.;Rapid urease test. Timepoint: Four weeks after the last day of treatment. Method of measurement: Standard protocol.;Helicobacter pylori stool antigen. Timepoint: Four weeks after the last day of treatment. Method of measurement: Standard protocol.	—

Measure

Time frame

Helicobacter pylori in the corpus specimen. Timepoint: Four weeks after the last day of treatment. Method of measurement: Standard protocol.;Histopathology of stomach biopsy. Timepoint: Four weeks after the last day of treatment. Method of measurement: Standard protocol.;Helicobacter pylori in anther sample. Timepoint: Four weeks after the last day of treatment. Method of measurement: Standard protocol.;Rapid urease test. Timepoint: Four weeks after the last day of treatment. Method of measurement: Standard protocol.;Helicobacter pylori stool antigen. Timepoint: Four weeks after the last day of treatment. Method of measurement: Standard protocol.

—

Secondary

Measure	Time frame
Body mass index. Timepoint: Four weeks after the last day of treatment. Method of measurement: Body mass index formula.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRita Baqerian

Qazvin University of Medical Sciences

md.yar88@yahoo.com+98 28 3333 6001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026